CLAIMS

What is claimed is:

1. A method for treating anxiety comprising:

preparing modified trimethylglycine and cofactors by subjecting said trimethylglycine and

cofactors to laser radiation; and ingesting an effective amount of said modified trimethylglycine

and cofactors.

2. The method for treating anxiety according to claim 1, wherein said method comprises

consuming at least 2 grams of modified trimethylglycine and cofactors daily.

3. The method for treating anxiety according to claim 1, wherein said method comprises

consuming at least 4 grams of modified trimethylglycine and cofactors daily.

4. The method for treating anxiety according to claim 1, wherein said method comprises

consuming at least 6 grams of modified trimethylglycine and cofactors daily.

5. The method for treating anxiety according to claim 1, wherein the method comprises forming

said modified trimethylglycine and cofactors by exposure to laser radiation with an amplitude

modulation at a resonance frequency of one or more acoustic vibration frequencies of said

trimethylglycine and cofactors and said laser radiation is structured in polarization and wave

patterns.

6. A method for treating depression comprising:

BATEMAN IP LAW GROUP 4 TRIAD CENTER, SUITE 825 P.O. Box 1319 SALT LAKE CITY, UTAH 84110

preparing modified trimethylglycine and cofactors by subjecting said trimethylglycine and

cofactors to laser radiation; and

ingesting an effective amount of said modified trimethylglycine and cofactors.

7. The method for treating depression according to claim 6, wherein said method comprises

consuming at least 2 grams of modified trimethylglycine and cofactors daily.

8. The method treating depression according to claim 6, wherein said method comprises

consuming at least 4 grams of modified trimethylglycine and cofactors daily.

9. The method for treating depression according to claim 6, wherein said method comprises

consuming at least 6 grams of modified trimethylglycine and cofactors daily.

10. The method for treating depression according to claim 6, wherein the method comprises

forming said modified trimethylglycine and cofactors by exposure to laser radiation with an

amplitude modulation at a resonance frequency of one or more acoustic vibration frequencies of

said trimethylglycine and cofactors and said laser radiation is structured in polarization and wave

patterns.

11. A method for treating obsessive-compulsive symptoms comprising: preparing modified

trimethylglycine and cofactors by subjecting said trimethylglycine and cofactors to laser

radiation; and

ingesting an effective amount of said modified trimethylglycine and cofactors.

BATEMAN IP LAW GROUP 4 TRIAD CENTER, SUITE 825 P.O. BOX 1319

SALT LAKE CITY, UTAH 84110

12. The method for treating obsessive-compulsive symptoms according to claim 11, wherein

said method comprises consuming at least 2 grams of modified trimethylglycine and cofactors

daily.

13. The method for treating obsessive-compulsive symptoms according to claim 11, wherein

said method comprises consuming at least 4 grams of modified trimethylglycine and cofactors

daily.

14. The method for treating obsessive-compulsive symptoms according to claim 11, wherein

said method comprises consuming at least 6 grams of modified trimethylglycine and cofactors

daily.

15. The method for treating obsessive-compulsive symptoms according to claim 11 wherein the

method comprises forming said modified trimethylglycine and cofactors by exposure to laser

radiation with an amplitude modulation at resonance frequency of one or more acoustic vibration

frequencies of said trimethylglycine and cofactors and said laser radiation is structured in

polarization and wave patterns.

16. A method for treating paranoia comprising:

preparing modified trimethylglycine and cofactors by subjecting said trimethylglycine and

cofactors to laser radiation; and ingesting an effective amount of said modified trimethylglycine.

83

BATEMAN IP LAW GROUP 4 TRIAD CENTER, SUITE 825 P.O. Box 1319

SALT LAKE CITY, UTAH 84110

17. The method for treating paranoia according to claim 16, wherein said method comprises

consuming at least 2 grams of modified trimethylglycine and cofactors daily.

18. The method for treating paranoia according to claim 16, wherein said method comprises

consuming at least 4 grams of modified trimethylglycine and cofactors daily.

19. The method for treating paranoia according to claim 17,

wherein said method comprises consuming at least 6 grams of modified trimethylglycine and

cofactors daily.

20. The method for treating paranoia according to claim 16, wherein the method comprises

forming said modified trimethylglycine and cofactors by exposure to laser radiation with an

amplitude modulation at a resonance frequency of one or more acoustic vibration frequencies of

said trimethylglycine and cofactors and said laser radiation is structured in polarization and wave

patterns.

21. A method for treating hostility comprising:

preparing modified trimethylglycine and cofactors by subjecting said trimethylglycine and

cofactors to laser radiation; and ingesting an effective amount of said modified trimethylglycine

and cofactors.

22. The method for treating hostility according to claim 21, wherein said method comprises

consuming at least 2 grams of modified trimethylglycine and cofactors daily.

BATEMAN IP LAW GROUP 4 TRIAD CENTER, SUITE 825 P.O. Box 1319

SALT LAKE CITY, UTAH 84110

23. The method for treating hostility according to claim 21, wherein said method comprises

consuming at least 4 grams of modified trimethylglycine and cofactors daily.

24. The method for treating hostility according to claim 21, wherein said method comprises

consuming at least 6 grams of modified trimethylglycine and cofactors daily.

25. The method for treating hostility according to claim 21, wherein the method comprises

forming said modified trimethylglycine and cofactors by exposure to laser radiation with an

amplitude modulation at a resonance frequency of one or more acoustic vibration frequencies of

said trimethylglycine and cofactors and said laser radiation is structured in polarization and wave

patterns.

26. A method for treating perceptions of bodily distress, aches, and pains comprising: preparing

modified trimethylglycine and cofactors by subjecting said trimethylglycine and cofactors to

laser radiation; and ingesting an effective amount of said modified trimethylglycine and

cofactors.

27. The method for treating perceptions of bodily distress, aches, and pains according to claim

26, wherein said method comprises consuming at least 2 grams of modified trimethylglycine and

cofactors daily.

BATEMAN IP LAW GROUP 4 TRIAD CENTER, SUITE 825 P.O. BOX 1319 SALT LAKE CITY, UTAH 84110

28. The method for treating perceptions of bodily distress, aches, and pains according to claim

26, wherein said method comprises consuming at least 4 grams of modified trimethylglycine and

cofactors daily.

29. The method for treating perceptions of bodily distress, aches, and pains according to claim

26, wherein said method comprises consuming at least 6 grams of modified trimethylglycine and

cofactors daily.

30. The method for treating perceptions of bodily distress, aches, and pains according to claim

26, wherein the method comprises forming said modified trimethylglycine and cofactors by

exposure to laser radiation with an amplitude modulation at resonance frequency of one or more

acoustic vibration frequencies of said trimethylglycine and cofactors and said laser radiation is

structured in polarization and wave patterns.

31. A method for treating autoimmune disorders comprising: preparing modified betaine and

cofactors by subjecting said betaine and cofactors to laser radiation; and ingesting an effective

amount of said modified betaine and cofactors.

32. The method for treating autoimmune disorders according to claim 31, wherein said method

comprises consuming at least 6 grams of laser treated betaine plus cofactors daily for an

induction period of 2-3 months, followed by a maintenance dose of 1-2 grams of said laser

treated betaine plus cofactors daily to be maintained or adjusted based on clinical or biochemical

response.

BATEMAN IP LAW GROUP 4 TRIAD CENTER, SUITE 825 P.O. Box 1319 SALT LAKE CITY, UTAH 84110

33. The method for treating autoimmune disorders according to claim 31, wherein the method

comprises forming said modified betaine plus cofactors by exposure to laser radiation with an

amplitude modulation at a resonance frequency of one or more acoustic vibration frequencies of

said betaine plus cofactors and said laser radiation is structured in polarization and wave pattern.

34. A method for modifying amino acids to reduce the immune reaction to said amino acids, as

would be beneficial to provide systemic and tissue amino acids in inflammatory, autoimmune,

and allergic conditions, comprising: preparing modified amino acids by subjecting said amino

acids to laser radiation; and ingesting an effective amount of said modified amino acids.

35. The method for modifying amino acids to reduce the immune reaction to said amino acids

according to claim 34, wherein the method comprises forming said modified amino acids by

exposure to laser radiation with an amplified modulation at a resonance frequency of one or

more acoustic vibration frequencies of said amino acids and said laser radiation is structured in

polarization and wave pattern.

36. A method for modifying amino acids to reduce inflammation, through reducing

inflammatory cytokine production in response to said amino acids comprising: preparing

modified amino acids by subjecting said amino acids to laser radiation; and ingesting an effective

amount of said modified amino acids.

BATEMAN IP LAW GROUP 4 TRIAD CENTER, SUITE 825 P.O. Box 1319 SALT LAKE CITY, UTAH 84110

37. The method for modifying amino acids to reduce inflammation, through reducing

inflammatory cytokine production, according to claim 36, wherein the method comprises

forming said modified amino acids by exposure to laser radiation with an amplitude modification

at a resonance frequency of one or more acoustic vibration frequencies of said amino acids and

said laser radiation is structured in polarization and wave pattern.

38. A method for improving the quality of crystal formation through increased homogeneity of

unit cell elements or reduced defects in the crystal lattice, or both, comprising: selecting the

molecular species to be crystallized; and subjecting said molecular species to laser radiation

during the process of crystallization.

39. The method for improving the quality of crystal formation through increased homogeneity

of unit cell elements or reduced crystal defects or both according to claim 38, wherein the

method comprises subjecting the selected molecular species, during the crystallization process,

to laser radiation with an amplitude modulation at a resonance frequency of one or more acoustic

vibration frequencies of said molecular species, and said laser radiation is structured in

polarization and wave patterns.

40. A method for improving the quality of crystals that have already solidified through

homogenizing unit cell elements and/or liberating trapped water in the crystal lattice comprising:

selecting the crystal form to be homogenized and/or dried; and subjecting said crystal form to

laser radiation.

BATEMAN IP LAW GROUP 4 TRIAD CENTER, SUITE 825 P.O. BOX 1319 SALT LAKE CITY, UTAH 84110

OUP

41. The method for improving the quality of crystals that have already solidified through

homogenizing unit cell elements and/or drying according to claim 40, wherein the method

comprises subjecting said selected crystal form to laser radiation with an amplitude modulation

at a resonance frequency of one or more acoustic vibration frequencies of the molecular species

of said selected crystal form, and said laser radiation is structured in polarization and wave

patterns.

42. A method for generating highly crystalline and homogeneous simvastatin comprising:

dissolving simvastatin in a solvent and subjecting said simvastatin to laser radiation during the

crystallization process.

43. The method for generating highly crystalline and homogeneous simvastatin according to

claim 42, wherein the method comprises dissolving said simvastatin in a solvent and subjecting

said simvastatin to laser radiation with an amplitude modulation at a resonance frequency of one

or more acoustic vibration frequencies of said simvastatin, and said laser radiation is structured

in polarization and wave patterns.

44. A method for generating amorphous simvastatin comprising: dissolving simvastatin in a

solvent and subjecting said simvastatin to laser radiation during the crystallization process.

45. The method for generating amorphous simvastatin according to claim 44, wherein the

method comprises dissolving said simvastatin in ethanol or another solvent and subjecting said

simvastatin to laser radiation with an amplitude modulation at a resonance frequency of one or

BATEMAN IP LAW GROUP 4 TRIAD CENTER, SUITE 825 P.O. Box 1319 SALT LAKE CITY, UTAH 84110

more acoustic vibration frequencies of said simvastatin, and said laser radiation is structured in

polarization and wave patterns.

46. A method for modifying the activity of an enzyme, substrate, or ligand, the method

comprising: selecting an enzyme, substrate, or ligand to be modified; and subjecting said

enzyme, substrate, or ligand to laser irradiation to modify the structure thereof.

47. The method for modifying the activity of an enzyme, substrate, or ligand according to claim

46, wherein the method comprises selecting an enzyme, substrate, or ligand to be modified; and

subjecting said enzyme, substrate or ligand to laser radiation with an amplitude modulation at a

resonance frequency of one or more acoustic vibration frequencies of said enzyme, substrate or

ligand to modify the structure thereof, and said laser radiation is structured in polarization and

wave patterns.

48. A method of increasing the depth of penetration of laser electromagnetic signals and energy

through tissue to enhance the depth and range of therapeutic efficiency of photodynamic therapy,

this method comprising: identifying a condition in tissue that may be responsive to

photodynamic therapy; and determining a suitable photodynamic compound, photoactivating

laser wavelength, and laser radiation dose to use for treatment of said condition; and

administering said photodynamic compound and allowing sufficient time for accumulation of

said compound in said tissue to be treated; and applying a sufficient dose of sparse constructive

nodes of laser radiation to the tissue to be treated via external beam, endoscopically, endarterially

or other route as appropriate, with said laser radiation having an amplitude modulation at a

BATEMAN IP LAW GROUP 4 TRIAD CENTER, SUITE 825 P.O. Box 1319

SALT LAKE CITY, UTAH 84110

resonant frequency of one or more acoustic vibration frequencies of said photodynamic compound, and said laser radiation is structured in polarization and wave pattern.

49. A method of homogenizing, flattening, and reducing the distortion of backbone twist of aromatic amino acids and L-dopa, and any other dopaminergic, catecholaminergic, or serotonergic precursor, compound, or pharmaceutical agent to enhance the bioavailability of the modified molecular structure, the method comprising: selecting the dopaminergic, catecholaminergic, or serotonergic precursor, compound, or pharmaceutical agent to be modified; and treating said dopaminergic, catecholaminergic, or serotonergic precursor, compound, or pharmaceutical agent with laser radiation.

- 50. The method of homogenizing, flattening, and reducing the distortion of backbone twist distortion of aromatic amino acids and any other dopaminergic, catecholaminergic, or serotonergic precursor, compound, or pharmaceutical agent to enhance the bioavailability of the modified molecular structure according to claim 49, wherein said method comprises selecting a dopaminergic, catecholaminergic, or serotonergic precursor, compound or pharmaceutical agent to be modified; and treating said dopaminergic, catecholaminergic, or serotonergic precursor, compound or pharmaceutical agent with laser radiation, with an amplitude modulation at a resonance frequency of one or more acoustic vibration frequencies of said precursor, compound or pharmaceutical agent, and said laser radiation is structured in polarization and wave pattern.
- 51. A method of homogenizing, flattening, and reducing the distortion of backbone twist of a nutrient, pharmaceutical agent, or other bioactive substance to enhance the bioavailability of the modified substance, the method comprising: selecting a nutrient, pharmaceutical agent, or other

BATEMAN IP LAW GROUP 4 TRIAD CENTER, SUITE 825 P.O. BOX 1319 SALT LAKE CITY, UTAH 84110 bioactive substance to modify; and treating said nutrient, pharmaceutical agent, or other

bioactive substance with laser radiation.

52. The method of homogenizing, flattening, and reducing the distortion of backbone twist of a

nutrient, pharmaceutical agent, or other bioactive substance to enhance the bioavailability of the

modified substance according to claim 51, wherein said method comprises selecting a nutrient,

pharmaceutical agent, or other bioactive substance to modify; and treating said nutrient,

pharmaceutical agent, or other bioactive substance with laser radiation with an amplitude

modulation at a resonant frequency at one or more acoustic vibration frequencies of said nutrient,

pharmaceutical agent, or other bioactive substance, and said laser radiation is structured in

polarization and wave patterns.

53. A method for increasing the bioavailability of nucleic acid bases, nucleosides or

deoxynucleosides, or nucleotide or deoxynucleotide monophosphates, diphosphates, or

triphosphates, the method comprising: selecting a nucleic acid base, nucleoside or

deoxynucleoside, or nucleotide or deoxynucleotide monophosphate, diphosphate, or

triphosphate; and subjecting said selected substance to laser radiation to modify the structure

thereof.

54. The method for increasing the bioavailability of nucleic acid bases, nucleosides or

deoxynucleosides, or nucleotide or deoxynucleotide monophosphates, diphosphates, or

triphosphates according to claim 53, wherein the method comprises selecting a nucleic acid

base, nucleoside or deoxynucleoside, or nucleotide or deoxynucleotide monophosphate,

diphosphate, or triphosphate to modify; and subjecting said nucleic acid base, nucleoside or

BATEMAN IP LAW GROUP 4 TRIAD CENTER, SUITE 825 P.O. BOX 1319

SALT LAKE CITY, UTAH 84110

deoxynucleoside, or nucleotide or deoxynucleotide monophosphate, diphosphate, or triphosphate

to laser radiation with an amplitude modulation at a resonance frequency of one or more acoustic

vibration frequencies of said nucleic acid base, nucleoside or deoxynucleoside, or nucleotide or

deoxynucleotide monophosphate, diphosphate, or triphosphate, and said laser radiation is

structured in polarization and wave patterns.

55. A method of increasing the bioactivity of high energy phosphates of nucleotides or

deoxynucleotides, the method comprising: selecting a nucleotide or deoxynucleotide to modify;

and subjecting said nucleotide or deoxynucleotide to laser radiation.

56. The method of increasing the bioactivity of high energy phosphates of nucleotides or

deoxynucleotides according to claim 55, wherein the method comprises selecting a nucleotide or

deoxynucleotide to modify; and subjecting said nucleotide or deoxynucleotide to laser radiation

with an amplitude modulation at a resonance frequency of one or more acoustic vibration

frequencies of high energy phosphates of said nucleotide or deoxynucleotide, and said laser

radiation is structured in polarization and wave pattern.

57. A method of increasing the bioavailability of a nucleic acid base, nucleoside or

deoxynucleoside, or nucleotide or deoxynucleotide monophosphate, diphosphate, or triphosphate

whether or not it has been modified with laser treatment according to claim 128, the method

comprising: making a solution of said nucleic acid base, nucleoside, or nucleotide

monophosphate, diphosphate, or triphosphate with a concentration at least 10 times that of blood

plasma; and applying said solution for at least 30 seconds to oral or other nonintestinal mucosa

BATEMAN IP LAW GROUP 4 TRIAD CENTER, SUITE 825 P.O. Box 1319 SALT LAKE CITY, UTAH 84110

for direct transmucosal absorption to overcome the extensive degradation of nucleic acid

elements as occurs in intestinal mucosa.

58. A method for amplifying or modifying the production or purification of a selected

stereoisomer or epimer of a bioactive substance, the method comprising: selecting the

stereoisomer to amplify or modify; and subjecting said stereoisomer or epimer to rotationally

polarized laser light, with an amplitude modulation at a resonance frequency at one or more

acoustic vibration frequencies of said stereoisomer or epimer, and said laser radiation is

structured in polarization and wave pattern.

59. A method of reshaping prions or other pathogenic proteins to reduce their pathogenicity,

said method comprising: selecting a prion or other pathogenic protein to reshape; and subjecting

said prion or other pathogenic protein to laser radiation.

60. The method of reshaping prions or other pathogenic proteins to reduce their pathogenicity

according to claim 59, wherein said method comprises selecting a prion or other pathogenic

protein to reshape; and subjecting said prion or other pathogenic protein to laser radiation with

an amplitude modulation at a resonance frequency of one or more acoustic vibration frequencies

of said prion or other pathogenic protein, and said laser radiation is structured in polarization and

wave pattern.

61. The method of reshaping prions or other pathogenic proteins to reduce their pathogenicity

94

according to claim 60, wherein said method comprises selecting a prion or other pathogenic

BATEMAN IP LAW GROUP 4 TRIAD CENTER, SUITE 825 P.O. BOX 1319

SALT LAKE CITY, UTAH 84110

protein to reshape; and determining the peak absorption frequencies of said prions or other

pathogenic proteins and their nonpathogenic counterparts using sonoluminescence with CO₂

nucleation absorption spectrum analysis or other spectroscopic method or mathematical

modeling; and subjecting said prions or other pathogenic proteins to laser radiation with an

amplitude modulation of one or more peak absorption frequencies of normal protein, the

pathogenic protein, or the differential absorption pattern between the normal and pathogenic

counterpart protein to reshape said prions or other pathogenic proteins to reduce their

pathogenicity, and said laser radiation is structured in polarization and wave patterns.

62. A method of reshaping pathogenic substances or components of infectious pathogens to

reduce their pathogenicity, said method comprising: selecting a pathogenic substance or one or

more components of an infectious pathogen to reshape; and subjecting said pathogenic substance

or one or more components of said infectious pathogen to laser radiation.

63. The method of reshaping pathogenic substances or components of infectious pathogens to

reduce their pathogenicity according to claim 62, wherein said method comprises selecting a

pathogenic substance or one or more components of an infectious pathogen to reshape; and

subjecting said pathogenic substance or one or more components of said infectious pathogen to

laser radiation, with an amplitude modulation at a resonance frequency of one or more acoustic

vibration frequencies of said pathogenic substance or of one or more components of said

infectious pathogen, and said laser radiation is structured in polarization and wave pattern.

64. The method of reshaping pathogenic substances or components of infectious pathogens to

reduce their pathogenicity according to claim 63, wherein said method comprises selecting a

BATEMAN IP LAW GROUP 4 TRIAD CENTER, SUITE 825 P.O. Box 1319

SALT LAKE CITY, UTAH 84110

pathogenic substance or one or more components of an infectious pathogen to reshape; and

determining the peak absorption frequencies of said pathogenic substance or one or more

components of said infectious pathogen using sonoluminescence with CO₂ nucleation absorption

spectrum analysis or other spectroscopic method or mathematical modeling; and subjecting said

pathogenic substance or one or more components of said infectious pathogen to laser radiation,

with an amplitude modulation of one or more peak absorption frequencies of said pathogenic

substance or of one or more components of said infectious pathogen, and said laser radiation is

structured in polarization and wave pattern.

65. A method of selectively activating specific regions of selected molecules to increase the

production of desired products in a chemical reaction, to generate novel reaction sequences for

products, or to generate the production of novel products with specific molecular shapes,

properties, and activities, said method comprising: selecting one or more molecular species to

modify; and subjecting said molecular species to laser radiation.

66. The method of selectively activating specific regions of selected molecules to increase the

production of desired products in a chemical reaction, to generate novel reaction sequences for

products, or to generate the production of novel products with specific molecular shapes,

properties, and activities according to claim 65, wherein said method comprises selecting one or

more molecular species to modify; and subjecting said molecular species to laser radiation with

an amplitude modulation at a resonance frequency of one or more acoustic vibration frequencies

of said molecular species, and said laser radiation is structured in polarization and wave pattern.

BATEMAN IP LAW GROUP 4 TRIAD CENTER, SUITE 825 P.O. BOX 1319 SALT LAKE CITY, UTAH 84110

67. The method of selectively activating specific regions of selected molecules to increase the

production of desired products in a chemical reaction, to generate novel reaction sequences for

products, or to generate the production of novel products with specific molecular shapes,

properties, and activities according to claim 66, wherein said method comprises selecting one or

more molecular species to modify; and determining the peak absorption frequencies of said

specific regions of selected molecular species to be modified using sonoluminescence with CO₂

nucleation absorption spectrum analysis, other spectrographic method, or through mathematical

molecular modeling; and subjecting said molecular species to laser radiation with an amplitude

modulation of one or more peak absorption frequencies of said molecular species, and said laser

radiation is structured on polarization and wave pattern.

68. A method of selectively activating molecular species or specific regions of molecular

species to generate a signal for qualitative or quantitative detection or analysis, said method

comprising: selecting a specific molecular species or region of a molecular species to activate

through resonance; and subjecting said molecular species to laser radiation with an amplitude

modulation at a resonance frequency of one or more acoustic vibration frequencies of said

molecular species, and said laser radiation is structured in polarization and wave pattern.

69. The method of selectively activating molecular species or specific regions of molecular

species to generate a signal for qualitative or quantitative detection or analysis according to claim

68, wherein said method comprises selecting a specific molecular species or region of a

molecular species to activate through resonance; and determining the peak absorption

frequencies of said specific molecular species or region of a molecular species using

sonoluminescence with CO₂ nucleation absorption spectrum analysis, other spectrographic

BATEMAN IP LAW GROUP 4 TRIAD CENTER, SUITE 825 P.O. Box 1319 SALT LAKE CITY, UTAH 84110

method, or through mathematical molecular modeling; and subjecting said molecular species to laser radiation with an amplitude modulation of one or more peak absorption frequencies of said molecular species, and said laser radiation is structured in polarization and wave pattern.

BATEMAN IP LAW GROUP 4 TRIAD CENTER, SUITE 825 P.O. BOX 1319 SALT LAKE CITY, UTAH 84110